Clinical Trial Update: 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD [Phase 3]

View source ↗

Summary

An 18-month Phase 3 study evaluating safinamide as add-on therapy for mid-to-late stage Parkinson's disease has completed, examining long-term efficacy and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED